Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Prostate specific antigen (PSA) is typically the first indicator of relapse in patients treated for prostate cancer. Though radiographic progression with an undetectable PSA is clearly documented in the literature, this is an unusual event. We describe two cases of patients treated with a combination of androgen deprivation and chemotherapy for early stage but high risk prostate cancer who manifested clear evidence of radiographic relapse despite PSA values of <0.1 ng/mL. We hypothesize that patients with early stage prostate cancer treated with combinations of androgen deprivation and chemotherapy may be at high risk for this unusual pattern of relapse.
Sartor
Oliver
O
Stanley Scott Cancer Center, New Orleans, Louisiana, USA.
D000813:Anilides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009570:Nitriles / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors; D014105:Tosyl Compounds / Q000627:therapeutic use
D000813:Anilides; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen; D016729:Leuprolide